Compare Ginkgo Bioworks Holdings Inc (DNA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs VF Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.02 (market cap $590.53M), while VF Corp trades at $17.17 (market cap $6.54B). The key difference: VF Corp is far larger — about 11.1× Ginkgo Bioworks Holdings Inc's market cap, and VF Corp pays a 2.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | VFC | |
|---|---|---|
Market Cap | $590.53M | $6.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $21.55 |
52-Week Low | $5.48 | $11.66 |
Enterprise Value | $627.78M | $10.69B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
VFC trades at $16.88, up 0.66% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Recent earnings show volatility with Q1 2026 missing estimates after previous beats. Revenue declined to $9.50B in 2025 with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a solid gross margin of 54.78% and reduced debt-to-asset ratio to 42.42% in 2025.
Outlook hinges on execution of turnaround efforts, particularly brand performance at Vans. Analyst consensus is mixed with a $19.33 price target suggesting 14.5% upside, but weak consumer spending and competitive pressures pose near-term risks. Cash flow improvement in 2026 projections and continued deleveraging provide potential catalysts if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
